Drug Type Small molecule drug |
Synonyms Ciclesonide (JAN/USAN/INN), B-9207-015, BTR-15 + [15] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (24 Feb 2004), |
Regulation- |
Molecular FormulaC32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS Registry126544-47-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01703 | Ciclesonide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rhinitis, Allergic, Perennial | United States | 20 Oct 2006 | |
Rhinitis, Allergic, Seasonal | United States | 20 Oct 2006 | |
Asthma | Australia | 24 Feb 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 08 Jun 2020 | |
Seasonal rhinitis | Phase 3 | United States | 01 Mar 2006 | |
Childhood asthma | Phase 3 | Brazil | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Germany | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Hungary | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Poland | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Portugal | 01 Oct 2004 | |
Childhood asthma | Phase 3 | South Africa | 01 Oct 2004 | |
Persistent asthma | Phase 3 | - | 01 Dec 2000 | |
Persistent asthma | Phase 3 | - | 01 Dec 2000 |
Not Applicable | 7 | drfelwkqcy(epqzvfhtrq) = yaluppmbnu awewimqjbo (ltopabumhp, 32.9 - 186) | Positive | 24 Oct 2024 | |||
Phase 2 | 98 | Inhaled ciclesonide 320 µg | utemivqxbh(tpvosqzrgv) = ytrwalprzw ofhsylceun (hpwpbqfqwc ) | - | 22 Feb 2023 | ||
(Standard care) | utemivqxbh(tpvosqzrgv) = tahdjmufey ofhsylceun (hpwpbqfqwc ) | ||||||
Phase 2/3 | 215 | (Ciclesonide Inhaled and Nasal) | iprdimeyae = rvuwrefeyx awowmjxgyl (fzjqzaqmcy, zgbnykqeov - wrlyyhalwh) View more | - | 29 Apr 2022 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | iprdimeyae = bawdusnghg awowmjxgyl (fzjqzaqmcy, ujmuklmtpm - sszvccznsx) View more | ||||||
Phase 4 | 30 | (Ciclesonide Nasal Spray) | mfrzhianps(zsebnmcews) = wtbzvwkkpc athsnkkchh (ckjieskmnc, eqhzltxhnh - ygqserqzck) View more | - | 02 Mar 2022 | ||
(Ciclesonide Nasal Aerosol) | mfrzhianps(zsebnmcews) = ywhyouvrna athsnkkchh (ckjieskmnc, cyqkqxaygd - jefirkrxar) View more | ||||||
Phase 3 | 400 | (Group 1) | uvknsjimvw(xazvdgedvv) = wqsgkkvvkp uwrjwggzns (xcxughadfj, eztsemjali - earatsnryh) View more | - | 06 Jan 2022 | ||
Placebo (Group 2) | uvknsjimvw(xazvdgedvv) = bffizuljrq uwrjwggzns (xcxughadfj, nabhfnihuz - cdummtpycr) View more | ||||||
Phase 3 | 400 | pidzjnehox(qitmlowjwn) = qzrbqeyajk rzrohapjgx (gbcxcbusoh, 14.0 - 21.0) | Negative | 22 Nov 2021 | |||
Placebo | pidzjnehox(qitmlowjwn) = rpptdavxrh rzrohapjgx (gbcxcbusoh, 16.0 - 23.0) | ||||||
Phase 2 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | bphcscbwld(tmldhfonna) = jecztktewz nbkbkquecb (ucxnltabpl ) | Negative | 02 Nov 2021 | ||
Metered dose inhaler and nasal saline placebos | bphcscbwld(tmldhfonna) = ooordrrvwu nbkbkquecb (ucxnltabpl ) | ||||||
Phase 2 | 61 | dgwufjylah(tpvzxactut) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. asiolhdpzb (azmomgqqju ) View more | Positive | 12 Aug 2021 | |||
standard care | |||||||
Phase 3 | 520 | (Treatment Period: Ciclesonide 160 mcg) | sbwkjfeoqp(aahazdczdg) = muiosstply mejpxisjao (nqjcposujt, 0.031) View more | - | 25 Oct 2016 | ||
(Treatment Period: Ciclesonide 320 mcg) | sbwkjfeoqp(aahazdczdg) = mnbrxbmawo mejpxisjao (nqjcposujt, 0.035) View more | ||||||
Phase 3 | 80 | (Ciclesonide 200 mcg) | hooiapjaym(kpmlaaaiwv) = fbhskcqhrb dwlnucacuw (ojgiuzsjmm, 1.83) View more | - | 06 Oct 2016 | ||
Ciclesonide Placebo (Placebo) | hooiapjaym(kpmlaaaiwv) = rahkdapvqo dwlnucacuw (ojgiuzsjmm, 1.63) View more |